Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The cost of removing financial barriers to treatment uptake and adherence as effective public health strategies for improving health and reducing HIV transmission in Australia Lance Feeney - Positive Life NSW (No conflicts of interest to declare) Background • The Australian Seventh National HIV Strategy 2014-2017 targets • NSW HIV Strategy 2012-2015: A New Era • Australian PBS subsidised medicines (patient co-payment) • Financial stress and cost of ART co-payments are barriers to treatment uptake and adherence • PLHIV experience higher rates of co-morbidity • Decisions about ART initiation and adherence are negatively impacted by cost of ART and non-ART medications Background cont. • A case for Australian Governments reducing the cost burden of ART, particularly for those experiencing financial stress • Annual cost of each new HIV infection is $13,800 - $16,300 for those on 1st or 2nd line ART • Annual cost for those on 3rd line ART is $19,000 • The life time cost of each new HIV infection is estimated to be approximately $483,000 - $570,000 (1st/2nd) and $665,000 (3rd line ART) Methods PBS Co-payment rates & employment percentages Number of ART items dispensed per person Full and Concessional patient cost for ART/non-ART medications over 12 months Yearly cumulative full co-payment cost of ARV and non-ARV medications ANTIRETROVIRALS 1item Total 221.00 2 items 442.00 3 items 663.00 4 items 884.00 NON-ANTIRETROVIRALS 1 item 2 items 3 items 442.00 884.00 1326.00 4 items 1768.00 5 items 2210.00 Yearly cumulative concessional co-payments costs for ARV and non-ARV medications ANTIRETROVIRALS 1 item Total 36.00 2 items 72.00 3 items 108.00 4 items 1441.00 NON-ANTIRETROVIRALS 1 item 2 items 3 items 72.00 144.00 216.00 4 items 288.00 5 items 360.00 Yearly cost to Government of waiving ART co-payments for 10,500 people with diagnosed HIV in NSW - 2014 Employed Full-time (59.6%) of 10,500 (6,258) Part-time/other (18.8%) of 10,500 (1,974) Concession (21.7%) of 10,500 (2,278) Total 70% treatment uptake $2,904,337 80% treatment uptake $3,319,242 90% treatment uptake $3,734,148 100% uptake $916,133 $1,047,009 $1,177,885 $1,308,762 $172,216 $196,819 $221,421 $246,024 $3,992,686 $4,563,070 $5,133,454 $5,703,840 $4,149,054 Yearly cost to Government of waiving co-payments for 15%-20% of people with undiagnosed HIV in NSW - 2014 Undiagnosed and untreated 15% of 10,500 (1,575) 20% of 10,500 (2,100 people) 70% treatment uptake $598,903 80% treatment uptake $684,460 90% treatment uptake $770,018 100% uptake $798,537 $912,614 $1,026,691 $1,140,768 $855,576 So for less than $6 million per year 90% of all people with diagnosed and undiagnosed HIV could be treated free It could cost $5.2 million per year at 80% treatment uptake Progress in other Australian States and Territories • New South Wales • Victoria - Detailed analysis commissioned by Victorian AIDS Council and Living Positive Victoria and conducted by Burnet Institute • • • • Queensland – South Australia – Western Australia – Northern Territory – Proposal viewed with merit, but yet to be approved for implementation Positive Life South Australia developing state-based submission ART co-payments waived ART co-payments waived • Tasmania and the Australian Capital Territory ? Conclusion • Mixed result to reduce cART cost burden • Improving rates of ART in NSW • But, still PLHIV minority with poorer health, drug and alcohol and poverty issues • Achieving 2015 treatment and prevention targets will require addressing barriers to cART • A case to build this into the public health response Acknowledgments • • • • • Jo Watson – NAPWHA (co-author) Bill Whittaker – NAPWHA Albion Centre Pharmacy St. Vincent’s Hospital Pharmacy PozAction members: o Queensland Positive People o Living Positive Victoria o Positive Life South Australia